A renowned biopharmaceutical company called Myogen Inc. which is concentrating on the discovery, development and commercialization of smaller molecule therapeutics for the treatments of cardiovascular diseases has initiated the clinical trial for assessing Ambrisentan on the patients having Pulmonary Arterial Hypertension – PAH who have earlier terminated similar therapies because of liver function test aberrations like elevated serum amino transferals concentrations in particular. 

Ambrisentan is the drug which is already under research for its use in the treatment of pulmonary hypertension. The drug is intended to work as an Endothelin Receptor Agonist and is selective for the type A Endothelin Receptors - ETA. It is an oral therapy for the patients having PAH and the drug has been designated as the orphan drug for the treatments of PAH in both the United States and European Union. Ambrisentan is under the advanced stage of 3rd clinical trial, testing for its safety and efficacy as the PAH drug.

Pulmonary Arterial Hypertension – PAH is the fatal sort of lung disorder that has been distinguished by the higher-than-normal i.e. over 25mm / HG blood pressure in the pulmonary artery. PAH is sometimes referred as the primary pulmonary hypertension – PPH that could develop degradation of the heart and lungs, concluding in the death of the patient. This drug is one of the few latest developed vasodilators that typically aim the ETA receptors, reducing their action and preventing vasoconstriction. The drug is still under the official clinical trial stage and awaits clearance by the US – FDA. It is intended to function as the once a day oral medication.